Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosis - A concise review

Thrombosis Research

Volumn 127, Issue 6, 2011, Pages 505-512

  Shetty, Shrimati ^a   Ghosh, Kanjaksha ^a  

^a KEM HOSPITAL   (India)

Author keywords

Budd chiari syndrome; Portal vein thrombosis; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DIHYDROFOLATE REDUCTASE; FIBRINOLYTIC FACTOR; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

BEHCET DISEASE; BUDD CHIARI SYNDROME; DISEASE ASSOCIATION; ENTERITIS; FIBRINOLYSIS; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; LIVER VEIN THROMBOSIS; MYELOPROLIFERATIVE DISORDER; NUTRITIONAL DISORDER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOPHILIA; TUMOR;

BUDD-CHIARI SYNDROME; HUMANS; LIVER DISEASES; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 79957608554     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.09.019     Document Type: Review

References (93)

1. Heller C, Schobess R, Kurnik K, Junker R, Günther G, Kreuz W, et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. Br J Haematol 2000;111:534-9.
2. Madonna P, De Stefano V, Coppola A, Cerbone AM, Di Minno G. G20210A prothrombin gene mutation and other trombophilic polymorphisms in patients with portal or hepatic venous thrombosis. Gastroenterology 2001;120:1059-60. (Pubitemid 32193205)
3. Darwish Murad S, Valla DC, de Groen PC, Zeitoun G, Haagsma EB, Kuipers EJ, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol 2006;101:83-90. (Pubitemid 43381713)
4. Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001;34: 666-70. (Pubitemid 32927989)
5. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-8.
6. Uskudar O, Akdogan M, Sasmaz N, Yilmaz S, Tola M, Sahin B. Etiology and portal vein thrombosis in Budd-Chiari syndrome. World J Gastroenterol 2008;14: 2858-62.
7. Bhattacharyya M, Makharia G, Kannan M, Ahmed RP, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol 2004;121:844-7. (Pubitemid 38669278)
8. Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587-91. (Pubitemid 30118625)
9. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005;41:603-8. (Pubitemid 40289509)
10. Mangia A, Villani MR, Cappucci G, Santoro R, Ricciardi R, Facciorusso D, et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005;17:745-51. (Pubitemid 40896421)
11. Ordi J, Vargas V, Vilardell M, Barquinero J, Guardia J. Lupus anticoagulant and portal hypertension. Am J Med 1988;84:566-8.
12. Li XM, Wei YF, Hao HL, Hao YB, He LS, Li JD, et al. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am J Hematol 2002;71:11-4.
13. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A. European Group for the Study of Vascular Disorders of the Liver. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003;38:364-71.
14. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to APC. Nature 1994;369:64-7. (Pubitemid 24144355)
15. Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, et al. Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost 1997;77:329-31. (Pubitemid 27084925)
16. Simkova M, Batorova A, Dostalova K, Pozgayova S, Simko F, Kovacs L. Factor V Leiden in patients with venous thrombosis in Slovak population. Gen Physiol Biophys 2004;23:435-42. (Pubitemid 40352624)
17. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg->Gln mutation in the gene for factor V. N Engl J Med 1994;331:1559-62. (Pubitemid 24366903)
18. Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997;40:798-800. (Pubitemid 27305476)
19. Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Brière J, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001;48:264-8. (Pubitemid 32141854)
20. Kumar SI, Kumar A, Srivastava S, Saraswat VA, Aggarwal R. Low frequency of factor V Leiden and prothrombin G20210A mutations in patients with hepatic venous outflow tract obstruction in northern India: a case-control study. Indian J Gastroenterol 2005;24:211-5. (Pubitemid 44317706)
21. Das R, Garewal G, Chawla Y, Dhiman RK. Prevalence of the factor V Leiden mutation in portal and hepatic vein thrombosis. Gut 1998;43:147. (Pubitemid 28335506)
22. Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010;51:210-8.
23. Chamouard P, Pencreach E, Maloisel F, Grunebaum L, Ardizzone JF, Meyer A, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999;116:144-8. (Pubitemid 29013503)
24. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000;31:345-8. (Pubitemid 30078598)
25. Salama K, El-Koofy N, El-Hawary M, El-Raziky M, Abou-El Ela M, Ali H, et al. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol 2004;83:712-5. (Pubitemid 39440216)
26. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002;70:126-32.
27. Ghosh K, Shetty S, Madkaikar M, Pawar A, Nair S, Khare A, et al. Venous thromboembolism in young patients from western India: a study. Clin Appl Thromb Hemost 2001;7:158-65. (Pubitemid 32242194)
28. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;15 (88):3698-703. (Pubitemid 26383091)
29. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8. (Pubitemid 28163839)
30. 20210→A Transition Is a Risk Factor for Cerebral Venous Thrombosis. Stroke 1998;29:1765-9.
31. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost 2008;99:675-82. (Pubitemid 351694223)
32. Schwarz HP. Extra-hepatic synthesis of protein S. Thromb Haemost 1990;64: 333-4.
33. McClure S, Dincsoy HP, Glueck H. Budd-Chiari Syndrome and antithrombin III deficiency. Am J Clin Pathol 1982;78:236-41.
34. Sas G, Blaskó G, Petrö I, Griffin JH. A protein S deficient family with portal vein thrombosis. Thromb Haemost 1985;54:724.
35. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-76. (Pubitemid 29078298)
36. Albisetti M, Moeller A, Waldvogel K, Bernet-Buettiker V, Cannizzaro V, Anagnostopoulos A, et al. Congenital prothrombotic disorders in children with peripheral venous and arterial thromboses. Acta Haematol 2007;117:149-55. (Pubitemid 46496798)
37. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med 2007;167:497-501. (Pubitemid 46425663)
38. Gabr MA, Bessa SS, El-Zamarani EA. Portal vein thrombosis in Egyptian patients with liver cirrhosis: Role of methylenetetrahydrofolate reductase C677T gene mutation. Hepatol Res 2010;40:486-93.
39. Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005;17:339-43. (Pubitemid 40411221)
40. Kurnik K, Kreuz W, Horneff S, Düring C, Schobess R, Bidlingmaier C, et al. Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children-results of a multicenter studys. Haematologica 2007;92:982-5. (Pubitemid 350144247)
41. Shetty S, Vora S, Kulkarni B, Mota L, Vijapurkar M, Quadros L, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007;138:541-4. (Pubitemid 47063041)
42. de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, et al. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost 2007;97: 181-5. (Pubitemid 46592136)
43. Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol 2002;71:89-93.
44. Hoekstra J, Guimarães AH, Leebeek FW, Darwish Murad S, Malfliet JJ, Plessier A, et al. European Network for Vascular Disorders of the Liver (EN-Vie). Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood 2010;115:388-95.
45. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005;129:553-60. (Pubitemid 40769907)
46. Austin SK, Lambert JR. The JAK2 V617F mutation and thrombosis. Br J Haematol 2008;143:307-20.
47. Dudley JM, Westwood N, Leonard S, Eridani S, Pearson TC. Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol 1990;75:188-94. (Pubitemid 20185456)
48. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-90. (Pubitemid 35429665)
49. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005;80:947-58. (Pubitemid 40911470)
50. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8. (Pubitemid 40663494)
51. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61. (Pubitemid 40386783)
52. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352: 1779-90. (Pubitemid 40570926)
53. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7: 387-97. (Pubitemid 40544655)
54. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-92. (Pubitemid 40853184)
55. Bergamaschi GM, Primignani M, Barosi G, Fabris FM, Villani L, Reati R, et al. MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood 2008;111:4418.
56. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009;124:409-17.
57. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006;130:2031-8. (Pubitemid 43816970)
58. Goulding C, Uttenthal B, Foroni L, Duke V, Traore A, Kottaridis P, et al. The JAK2 (V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein. Int J Lab Hematol 2008;30:415-9.
59. Colaizzo D, Amitrano L, Tiscia GL, Iannaccone L, Gallone A, Grandone E, et al. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. Blood Coagul Fibrinolysis 2008;l(19):459-62.
60. De Stefano V, Fiorini A, Rossi E, Za T, Chiusolo P, Sica S, et al. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. Hepatology 2007;45:831-2. (Pubitemid 46450639)
61. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006;44:1528-34. (Pubitemid 44953658)
62. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007;5:55-61. (Pubitemid 44921067)
63. Bayraktar Y, Harmanci O, Büyükasik Y, Shorbagi AI, Sungur AH, Boylu CA, et al. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci 2008;53: 2778-83.
64. Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006;91:1712-3. (Pubitemid 46032973)
65. Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5: 859-61. (Pubitemid 46563588)
66. McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. Am J Clin Pathol 2007;127:736-43.
67. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008;111:4922-9.
68. Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009;113:5617-23.
69. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
70. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
71. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8. (Pubitemid 40663494)
72. Nseir B, Panicker J. Antiphospholipids antibodies in a 12-month-old presenting with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2008;25: 233-5. (Pubitemid 351574434)
73. Vora S, Shetty S, Salvi V, Satoskar P, Ghosh K. A comprehensive screening analysis of antiphospholipid antibodies in Indian women with fetal loss. Eur J Obstet Gynecol Reprod Biol 2008;137:136-40. (Pubitemid 351423458)
74. Mackworth-Young CG, Gharavi AE, Boey ML, Hughes GR. Portal and pulmonary hypertension in a case of systematic lupus erythematosus: possible relationship with a clotting abnormality. Eur J Rheumatol Inflamm 1984;7:71-4. (Pubitemid 16002268)
75. Takahaski C, Kumagai S, Tsubata R, Sorachi K, Ozaki S, Imura H, et al. Portal hypertension associated with anticardiolipin antibodies in a case of systemic lupus erythematosus. Lupus 1995;4:232-5.
76. Valla DC. Antiphospholipid antibodies: limitations and potential use in liver diseases. Gastroentérol Clin Biol 1996;20:723-6.
77. Perarnau JM, Bacq Y. Hepatic vascular involvement related to pregnancy, oral contraceptives, and estrogen replacement therapy. Semin Liver Dis 2008;28: 315-27.
78. Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986;90:807-11. (Pubitemid 16124755)
79. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behçet's disease. Am J Gastroenterol 1997;92: 858-62.
80. Socié G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996;348:573-7. (Pubitemid 26283888)
81. Martinelli I, Primignani M, Aghemo A, Reati R, Bucciarelli P, Fabris F, et al. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol 2009;50:916-22.
82. Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994;73:21-36.
83. Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500-8. (Pubitemid 38222192)
84. Okuda H, Yamagata H, Obata H, Iwata H, Sasaki R, Imai F, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995;22:1-9.
85. Kohli V, Pande GK, Dev V, Reddy KS, Kaul U, Nundy S. Management of hepatic venous outflow obstruction. Lancet 1993;342:718-22. (Pubitemid 23279768)
86. Lu CL, Chou YH, Hwang SJ, Chan CY, Lee SD. Membranous obstruction of inferior vena cava in Taiwan. J Gastroenterol Hepatol 1995;10:287-94.
87. Rector Jr WG, Xu YH, Goldstein L, Peters RL, Reynolds TB. Membranous obstruction of the inferior vena cava in the United States. Medicine (Baltimore) 1985;64: 134-43. (Pubitemid 15146903)
88. Vickers CR, West RJ, Hubscher SG, Elias E. Hepatic vein webs and resistant ascites. Diagnosis, management and implications. J Hepatol 1989;8:287-93. (Pubitemid 19132315)
89. Eapen CE, Mammen T, Moses V. Shyamkumar NK.Changing profile of Budd Chiari syndrome in India. Indian J Gastroenterol 2007;26:77-81. (Pubitemid 46910505)
90. Bismuth E, Hadengue A, Hammel P, Benhamou JP. Hepatic vein thrombosis in Behçet's disease. Hepatology 1990;11:969-74. (Pubitemid 20221032)
91. Hirshberg B, Shouval D, Fibach E, Friedman G, Ben-Yehuda D. Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome. J Hepatol 2000;32:574-8. (Pubitemid 30180376)
92. Amitrano L, Guardascione MA, Scaglione M, Pezzullo L, Sangiuliano N, Armellino MF, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007;102:2464-70. (Pubitemid 47631782)
93. DeLeve LD, Valla DC. Garcia-Tsao G; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009;49:1729-64.